The growth of Viagra and its influence on the medicinal landscape presents a intricate question for shareholders. While the initial sales figures were remarkable, the exclusivity has expired, leading to a wave of off-brand alternatives that are eroding revenue. In addition, the sector is facing issues related to aging trends and evolving healthc… Read More